Overview

A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)

Status:
Completed
Trial end date:
2016-03-31
Target enrollment:
0
Participant gender:
All
Summary
This multicenter, prospective study will evaluate the baseline participant characteristics (including biomarkers) associated with a variety of individual and composite clinical outcomes in participants with moderate to severe asthma initiating treatment with omalizumab.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Omalizumab
Criteria
Inclusion Criteria:

- Participants identified by the investigator as a candidate for treatment for asthma
with omalizumab

- Confirmation of access to omalizumab through insurance or other source of funding

Exclusion Criteria:

- Enrollment in any other concurrent clinical trial or observational study

- Participants for whom omalizumab treatment is contraindicated

- Participants who had a prior allergic reaction to omalizumab or its excipients

- Participants treated with omalizumab within the previous year

- Participants who received an experimental drug as part of another study within 3
months of enrollment